DENVER, Colo., Nov 17, 2025 (247marketnews.com)- Monday’s Power Hour is shaping up to be one of the most catalyst-heavy sessions in weeks, with traders zeroing in on a handful of names delivering blockbuster data, strategic developments, and rare commercialization milestones. These are the stocks to watch into the close and afterhours.
Fresh Off the Wire: Spider Silk Deliveries Begin: A Milestone Long Awaited by Shareholders
Just minutes before Power Hour began, Kraig Biocraft Laboratories (OTCQB:KBLB) dropped one of its most consequential updates to date: the company is now fulfilling a spider silk order for a globally recognized performance sports brand as part of a confidential pilot development program.
This is KBLB’s first confirmed commercial engagement with an elite-tier athletic manufacturer and it’s exactly the kind of real-world validation shareholders have been waiting years to see.
Kraig is now processing its next-generation recombinant spider silk into precision-engineered yarns tailored to the partner’s specifications, with delivery expected before the end of Q1. Even though the order is small by design, the strategic value is enormous:
- It marks the first time a major global brand will integrate Kraig’s spider silk into a high-performance, elite-level application.
- It demonstrates that Kraig’s multi-year production buildout is now translating into meaningful commercial opportunities.
- It highlights the company’s position as the only player delivering scalable, real recombinant spider silk, a material that has attracted billions in R&D efforts worldwide.
CEO Kim Thompson emphasized the significance of the collaboration, noting that it “underscores the growing recognition of our material’s potential in high-value, high-performance applications.”
With spider silk seen as a key to next-gen apparel, technical textiles, and defense materials, KBLB becomes one of today’s highest-beta speculative names into the close.
Phase 3 Blowout: Ziihera Moves Toward Becoming the New HER2 Standard in GEA
The oncology space lit up early today as Zymeworks (NASDAQ:ZYME) and Jazz (NASDAQ:JAZZ) reported landmark Phase 3 results positioning Ziihera (zanidatamab-hrii) as the potential new first-line standard for HER2-positive gastroesophageal adenocarcinoma.
This is the first Phase 3 trial ever to beat trastuzumab + chemo on progression-free survival and the combination with Tevimbra delivered statistically significant improvements in both OS and PFS, across PD-L1 positive and negative patients.
Key drivers heading into the close:
- Strong efficacy across endpoints
- Clean safety profile
- Supplemental BLA submission planned for 1H 2026
- Royalty/milestone upside potential for ZYME
- Continued validation of Zymeworks’ Azymetric platform
ZYME remains one of the day’s most-watched biotech names, while JAZZ is drawing renewed institutional attention as investors price in pipeline expansion.
Autonomix Medical (NASDAQ:AMIX) surged into the spotlight today after releasing newly detailed post-hoc subgroup data from its first-in-human pancreatic cancer pain study. The analysis showed broad, durable improvements in symptom burden, functional status, and overall quality of life, even in late-stage metastatic patients.
Key highlights:
- Symptom improvements of 14–32 points across responders
- Functional gains up to 25.56 points
- Global quality-of-life improvements as high as 25 points
- Results exceeded the EORTC’s clinically meaningful threshold at all measured timepoints
- 100% of responding patients achieved zero opioid use by 3 months
CEO Brad Hauser noted that the data “provides deeper insight into how and why our ablation approach is improving outcomes across varied patient types.”
With a U.S. multicenter clinical trial slated for 2026 and PoC 2 expanding the addressable market to multiple visceral cancers, AMIX has emerged as one of today’s most intriguing small-cap med-tech catalysts.
Lithium Demand Outlook Ignites Bullish Surge
Sigma Lithium (NASDAQ:SGML) is ripping higher after Reuters reported that Ganfeng Lithium Group chairman Li Liangbin expects global lithium demand to grow 30% to 40%, far above traditional forecasts.
With EV demand stabilizing and supply constraints lingering, SGML has quickly become one of today’s commodities momentum trades.
New Biomarker Data Strengthens the Case for Buntanetap in Parkinson’s With Amyloid Co-Pathology
Annovis Bio (NYSE:ANVS) delivered new data reinforcing the disease-modifying potential of buntanetap, showing:
- Cognitive improvement in Parkinson’s patients
- Stronger responses in patients with amyloid co-pathology
- Reductions in pTau217, total tau, and brain-derived tau
These findings add mechanistic clarity to buntanetap’s Phase 3 outcomes and expand the potential treatable population.
Senior VP Cheng Fang emphasized that “Parkinson’s patients who experience cognitive decline also have Alzheimer’s pathology, and our drug helps them.”
Depending on trading volume, ANVS may see continued speculative interest into afterhours.
Sinclair Takes 8.2% Stake, Scripps Board Responds Firmly
Media stocks warmed up this afternoon after Sinclair (NASDAQ:SBGI) disclosed an 8.2% stake in E.W. Scripps (NASDAQ:SSP). The Scripps board responded with a strong statement emphasizing its commitment to shareholder value while asserting it will “take all steps appropriate to protect the company and the company’s shareholders from the opportunistic actions of Sinclair or anyone else.”
This sets up a potential strategic standoff watched closely by media investors.
For more information about Kraig Labs’ spider silk technology and partnership opportunities, visit www.kraiglabs.com
Please click here to read the full Kraig Labs analyst report on 247marketnews.com.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) is a biotechnology company focused on the development and commercialization of spider silk-based fiber technologies. Through its proprietary silkworm-based genetic engineering platform, Kraig Labs produces high-performance, cost-effective, and scalable spider silk materials for use in defense, performance apparel, technical textiles, and medical applications.
For more information, please visit: www.kraiglabs.com
Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services.
About 24/7 Market News
24/7 Market News (247) is a leading market news platform for public companies. As a pioneer in digital media, 247 is dedicated to the swift distribution of financial market news and information. 247 takes great pride in creating innovative public relations campaigns that help clients reach the target audience.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247 is a third-party media provider and has been compensated for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. Please review 247’s Full Disclaimer https://www.247marketnews.com/disclaimer/. Please go to https://247marketnews.com/kblb-disclosure/ for further KBLB and 247marketnews.com disclosure information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
The post The Market’s Most Explosive Stocks Heading into the Close appeared first on 24/7 MarketNews.